Tg Therapeutics Stock Today
| TGTX Stock | USD 13.99 0.17 1.23% |
Performance0 of 100
| Odds Of DistressLess than 3
|
TG Therapeutics is trading at 13.99 as of the 19th of April 2024; that is 1.23% increase since the beginning of the trading day. The stock's open price was 13.82. TG Therapeutics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for TG Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of April 2023 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of December 1995 | Category Healthcare | Classification Health Care |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. The company has 154.42 M outstanding shares of which 34.36 M shares are at this time shorted by private and institutional investors with about 9.04 trading days to cover. More on TG Therapeutics
Moving together with TGTX Stock
| 0.69 | KZR | Kezar Life Sciences Financial Report 9th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 6th of May 2024
TGTX Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. TG Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding TG Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Michael Weiss | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering TG Therapeutics report their recommendations after researching TG Therapeutics' financial statements, talking to executives and customers, or listening in on TG Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering TG Therapeutics. The TGTX consensus assessment is calculated by taking the average forecast from all of the analysts covering TG Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to TG Therapeutics' liquidity, profitability, solvency, and operating efficiency, TG Therapeutics is doing better financially then in previous quarter. It has a moderate odds of reporting better financial numbers in May. Financial strength of TG Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
TG Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to TG Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand TG Therapeutics' financial leverage. It provides some insight into what part of TG Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
TG Therapeutics (TGTX) is traded on NASDAQ Exchange in USA. It is located in 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560 and employs 264 people. TG Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate TG Therapeutics's market, we take the total number of its shares issued and multiply it by TG Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. TG Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 154.42 M outstanding shares of which 34.36 M shares are at this time shorted by private and institutional investors with about 9.04 trading days to cover.
TG Therapeutics currently holds about 195.71 M in cash with (31.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45.
Check TG Therapeutics Probability Of Bankruptcy
Ownership AllocationTG Therapeutics shows a total of 154.42 Million outstanding shares. Over half of TG Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Hence, these institutions are subject to different rules and regulations than regular investors in TG Therapeutics. Please watch out for any change in the institutional holdings of TG Therapeutics as this could mean something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check TGTX Ownership Details
TGTX Stock Price Odds Analysis
Based on a normal probability distribution, the odds of TG Therapeutics jumping above the current price in 90 days from now is about 85.08%. The TG Therapeutics probability density function shows the probability of TG Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8347. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, TG Therapeutics will likely underperform. Additionally, tG Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of TG Therapeutics to move above the current price in 90 days from now is about 85.08 (This TG Therapeutics probability density function shows the probability of TGTX Stock to fall within a particular range of prices over 90 days) .
TGTX Stock Institutional Holders
Institutional Holdings refers to the ownership stake in TG Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of TG Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing TG Therapeutics' value.| Instituion | Recorded On | Shares | |
| Susquehanna International Group, Llp | 2023-12-31 | 1.9 M | |
| Woodline Partners Lp | 2023-12-31 | 1.8 M | |
| 683 Capital Management Llc | 2023-12-31 | 1.7 M | |
| Voloridge Investment Management, Llc | 2023-09-30 | 1.6 M | |
| Fmr Inc | 2023-12-31 | 1.6 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.5 M | |
| Schonfeld Strategic Advisors Llc | 2023-09-30 | 1.4 M | |
| Northern Trust Corp | 2023-12-31 | 1.4 M | |
| Nuveen Asset Management, Llc | 2023-12-31 | 1.4 M | |
| Vanguard Group Inc | 2023-12-31 | 13.7 M | |
| Blackrock Inc | 2023-12-31 | 10.8 M |
TG Therapeutics Historical Income Statement
TG Therapeutics Income Statement is one of the three primary financial statements used for reporting TGTX's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of TG Therapeutics revenue and expense. TG Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, TG Therapeutics' Net Income is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 22 M in 2024, whereas Research Development is likely to drop slightly above 45.7 M in 2024. View More FundamentalsTGTX Stock Against Markets
Picking the right benchmark for TG Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in TG Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for TG Therapeutics is critical whether you are bullish or bearish towards TG Therapeutics at a given time. Please also check how TG Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in TG Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
TG Therapeutics Corporate Directors
TG Therapeutics corporate directors refer to members of a TG Therapeutics board of directors. The board of directors generally takes responsibility for the TG Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of TG Therapeutics' board members must vote for the resolution. The TG Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Neil Herskowitz | Independent Director | Profile | |
| Yann Echelard | Director | Profile | |
| Mark Schoenebaum | Independent Director | Profile | |
| Jenna Bosco | Director of Investor Relations | Profile |
How to buy TGTX Stock?
Before investing in TG Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in TG Therapeutics. To buy TG Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of TG Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase TG Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located TG Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased TG Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as TG Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.
Already Invested in TG Therapeutics?
The danger of trading TG Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of TG Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than TG Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile TG Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether TG Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of TG Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tg Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tg Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for TGTX Stock analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is TG Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TG Therapeutics. If investors know TGTX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TG Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.09 | Revenue Per Share 1.646 | Quarterly Revenue Growth 548.638 | Return On Assets 0.0493 | Return On Equity 0.1157 |
The market value of TG Therapeutics is measured differently than its book value, which is the value of TGTX that is recorded on the company's balance sheet. Investors also form their own opinion of TG Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is TG Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TG Therapeutics' market value can be influenced by many factors that don't directly affect TG Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TG Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if TG Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TG Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.